Silence Therapeutics Plc logo

SLN

Materials

Silence Therapeutics Plc

$7.36+0.22 (+3.08%)LIVE

Live · NASDAQ · May 9, Close

AI Insight

What's Moving SLN Today?

No stock-specific AI insight has been generated for SLN yet. Check back soon — insights are generated from recent news analysis.

Fundamentals

Market Cap$348M
P/E Ratio
EPS
Dividend Yield
Dividend / Share
ROE
Profit Margin
Debt / Equity

Trading

Volume381K
Avg Volume (10D)
Shares Outstanding47.2M

SLN News

21 articles

All 21 articles loaded

Price Data

Open$7.09
Previous Close$7.14
Day High$7.39
Day Low$6.95
52 Week High
52 Week Low

About Silence Therapeutics Plc

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

88 employees
Listed September 8, 2020
MaterialsPHARMACEUTICAL PREPARATIONS

Company Details

Security TypeStock
ExchangeNASDAQ
Currency
Round Lot
SICPHARMACEUTICAL PREPARATIONS
CIK
Composite FIGI
Share Class FIGI